While regulatory controls on methadone clinics for opioid dependence resulted in treatment being physically and functionally isolated from conventional medical care, the delivery of an office-based treatment of buprenorphine and the buprenorphine/naloxone combination product over the last decade has facilitated the return of treatment to “mainstream medicine both for psychiatry and primary care.” (Source: Psychiatric Times)
Update on Opioid Dependence and Its Treatment
Next post: MonoSol Rx Announces Listing of Patent in FDA Orange Book for Suboxone(R) Sublingual Films